Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: The efficacy and safety of fingolimod for relapsing-remitting multiple sclerosis (RRMS) had been well verified in several large randomized controlled trials (RCTs) during the past decade. However, there are fewer systematic comparisons of different doses of fingolimod and whether the dos...
Saved in:
Main Authors: | Xin Wu (Author), Tao Xue (Author), Zilan Wang (Author), Zhouqing Chen (Author), Xuwei Zhang (Author), Wei Zhang (Author), Zhong Wang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yue Sun, et al.
Published: (2020) -
Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
by: Gasperini C, et al.
Published: (2013) -
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021) -
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
by: Martin Vališ, et al.
Published: (2023) -
Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
by: Feng J, et al.
Published: (2019)